Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Glatiramer acetate induced hepatotoxicity.
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
Enhancement of Chemotactic Cell Aggregation by Haptotactic Cell-To-Cell Interaction.
Betaseron (Interferon Beta-1b) for SC Injection
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
[Neurophysiology in Guillain-Barré syndrome].
Management of women with multiple sclerosis through pregnancy and after childbirth.
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Antagonism of histamine H4 receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis.
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis.
Clinically isolated syndromes.
Flupirtine in pain management: pharmacological properties and clinical use.
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
Trimesta (Oral Estriol)
Two endogenous retroviral loci appear to contribute to Multiple Sclerosis.
Interferon beta treatment of multiple sclerosis increases serum interleukin-7.
Preclinical studies of sex differences: a clinical perspective.
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.
Burden of neurological conditions in Canada.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Genzyme receives positive CHMP opinion for LEMTRADA™ (alemtuzumab) in Europe
Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
Oligodendrocyte development and myelination in GFP-transgenic zebrafish.
Leisure time activities of Iranian patients with multiple sclerosis: a qualitative study.
Pages
« first
‹ previous
…
40
41
42
43
44
45
46
47
48
…
next ›
last »